Skip to main content

Peer Review reports

From: Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Original Submission
27 Nov 2019 Submitted Original manuscript
24 Feb 2020 Reviewed Reviewer Report - Duncan Gilbert
12 Mar 2020 Reviewed Reviewer Report - Pashtoon Murtaza Kasi
26 Mar 2020 Author responded Author comments - Stefano Kim
5 Apr 2020 Author responded Author comments - Stefano Kim
Resubmission - Version 2
26 Mar 2020 Submitted Manuscript version 2
7 Apr 2020 Editorially accepted
25 Apr 2020 Article published 10.1186/s12885-020-06841-1

You can find further information about peer review here.

Back to article page